Evidence map›Paper›PMID 40025380›Full record

SynthesisJournal of gastrointestinal cancer2025

Sedighe Hosseini Shabanan, Parnian Shobeiri, Amir Hossein Behnoush, Maryam Haghshomar, Kathryn J Fowler, Robert J Lewandowski

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of gastrointestinal cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Sedighe Hosseini ShabananDepartment of Radiology, University of California, San Diego, CA, USA. Shosseinishabanan@health.ucsd.edu.
Parnian ShobeiriDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Amir Hossein BehnoushDepartment of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Maryam HaghshomarDepartment of Radiology, Northwestern University Feinberg School of Medicine, 676 N. Saint Clair Street, Arkes Family Pavilion, Suite 800, Chicago, IL, 60611, USA.
Kathryn J FowlerDepartment of Radiology, University of California, San Diego, CA, USA.
Robert J LewandowskiDepartment of Radiology, Section of Interventional Radiology, Northwestern University, Chicago, IL, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTransarterial radioembolization with yttrium-90 (

methodsMedical databases of PubMed, Embase, and Cochrane Library were systematically searched for all studies assessing the use of concomitant immunotherapy of ICI with TARE in patients with HCC. Patient characteristics, treatment protocols, treatment outcomes, treatment adverse events, and survival outcomes were extracted after the screening phase. The primary outcomes were overall survival (OS) and patient-free survival (PFS), while the secondary outcomes were imaging objective response (OR) and adverse events.

resultsAmong 3432 reviewed, ten studies were included in this systematic review, including four randomized controlled trials and six retrospective studies. These consisted of 413 patients with HCC, and seven studies included patients with Child-Pugh A or B7 scores. Most studies allowed advanced or intermediate HCC stages, but only two specified BCLC stages (B and C). Median tumor sizes ranged from 56 to 78.5 mm. Various agents with different administration schedules were used as ICIs for immunotherapy by different studies for the combination of

conclusionConcomitant treatment with

Indexed as

Carcinoma, HepatocellularEmbolization, TherapeuticImmune Checkpoint InhibitorsLiver NeoplasmsYttrium RadioisotopesCombined Modality TherapyHumansRandomized Controlled Trials as TopicTreatment OutcomeImmune Checkpoint InhibitorsYttrium-90Yttrium RadioisotopesHepatocellular carcinomaImmune checkpoint inhibitorTransarterial radioembolization

Identifiers

PMID40025380

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.